Here’s a very important – maybe paradigm shifting – press release on a study that challenges the current, broad-based recommendations for people to lower their cholesterol. My highlights. – Ilene
Pharmboy had this comment:
Good article, and I agree with most of what’s in it, from scientific standpoint. I am not a Doc, but I have worked on this area of research. There are a few things in the pipelines of several companies that may help the inflammation of the arteries when someone is on a statin, and [the biotech] VIAP is spearheading the trials for this exact study. Unfortunately, their drug is for a shorter term treatment, and the real trials will have to be a bodybag trial….either they preserve life, or don’t. Diet and exercise are the two biggest things we can do to stay healthy.
Treat the Risk, Not the Cholesterol: Study Challenges Current Cholesterol Recommendations
ANN ARBOR, Mich., Jan. 22 /PRNewswire-USNewswire/ — A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better.
Tailoring treatment to a patient’s overall heart attack risk, by considering all their risk factors, such as age, family history, and smoking status, was more effective, and used fewer high-dose statins, than current strategies to drive down cholesterol to a certain target, according to the U-M study.
While study authors support the use of cholesterol-lowering statins, they conclude that patients and their doctors should consider all the factors that put them at risk for heart attack and strokes.
The findings will be released online Monday ahead of print in the Annals of Internal Medicine.
"We’ve been worrying too much about people’s cholesterol level and not enough about their overall risk of heart disease," says Rodney A. Hayward, M.D., director of the Veterans Affairs Center for Health Services Research and Development and a professor of internal medicine at the University of Michigan Medical School.
The National Cholesterol Education Program recommends harmful LDL cholesterol levels should be less than 130 for most people. High risk patients should be pushed even lower — to less than 70.
The U-M study took a different approach, called tailored treatment, which uses a person’s risk factors and mathematical models to calculate the expected benefit of treatment, by considering:
— A person’s risk of a heart attack or stroke without treatment;
— How much a statin decreases the risk; and
— Potential harms from the treatment
"These are the three factors that determine the net benefit of a treatment. Our fixation on just one factor, LDL cholesterol, is leading us to often treat the wrong people," Hayward says.
In the recent study, U-M physicians who worked with Yale University School of Medicine used data from statin trials that included Americans ages 30-75 with no history of heart attack.
Study authors evaluated the benefit of five years of treatment that was tailored, on coronary artery disease risk factors such as age, family history, diabetes, high blood pressure, smoking status, and recently CRP, C-reactive protein.
The tailored approach was more efficient (more benefit per person treated) and prevented substantially more heart attacks, strokes and cardiovascular deaths than the currently recommended treat-to-target approaches.
The tailored strategy treated fewer individuals with high-dose statins and saved 500,000 more quality-adjusted life years.
"The bottom line message — knowing your overall heart attack risk is more important than knowing your cholesterol level," Hayward says. "If your overall risk is elevated, you should probably be on a statin regardless of what your cholesterol is and if your risk is very high, should probably be on a high dose of statin," the U-M physician says.
"However, if your LDL cholesterol is high, but your overall cardiac risk is low, taking a statin does not make sense for you," Hayward says. "If your cholesterol is your only risk factor and you’re younger, you should work on diet and exercise."
Research has increasingly emerged questioning the value of cholesterol targets and which of statins mechanisms is most important to preventing cardiac events. Cholesterol-lowering drugs work by blocking a key enzyme linked with LDL cholesterol production, but they initiate other changes in the body.
"Statins also affect inflammation on the inside of our blood vessels which is often what causes heart attacks and strokes — it’s not just a matter of cholesterol alone," he says.
Additional authors: Harlan M. Krumholz, M.D., Yale University School of Medicine, and Donna M. Zulman, M.D., Justin W. Timbie, Ph.D., and Sandeep Vijan, M.D, all of the VA Center for Health Services Research and Development, VA Ann Arbor Health Care System.
Funding: VA Health Services Research and Development Service’s Quality Enhancement Research Initiative and the Measurement Core of the Michigan Diabetes Research & Training Center of the National Institutes of Health.
Resources: University of Michigan Medical School http://www.med.umich.edu/medschool/ VA Center for Health Services Research and Development http://www.annarbor.hsrd.research.va.gov/ VA Ann Arbor Health System http://www.annarbor.va.gov/ National Cholesterol Education Program http://www.nhlbi.nih.gov/about/ncep/index.htm
This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com/.
Source: University of Michigan Health System
